General Neurology
Placebo and nocebo effects in neurologic disorders
Jun. 11, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Handwriting and drawings of the dominant left upper extremity in a 42-year-old left-handed man with multiple cerebrotendinous xanthomatosis-related sequelae: motor examination pre-DBS placement and 6 months post-DBS VIM placement. The man's sequelae included developmental delay, cataracts, epilepsy, diabetes, chronic pancreatitis, anxiety, depression, parkinsonism, and postural or action tremor. His cerebrotendinous xanthomatosis-tremor was successfully treated with unilateral thalamic ventral intermediate nucleus (VIM) DBS (deep brain stimulation). (Source: Rich AM, Karakoleva EV, McInerney J, Farace E, De Jesus S. Cerebrotendinous xanthomatosis tremor successfully controlled post-ventral intermediate nucleus-deep brain stimulation: a case report. Front Neurol 2023;14:1243379. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)